In individuals with co-morbidities, defective immune responses to SARS-CoV-2 may allow unrestricted viral replication which elicits hyperinflammation and severe complications such as acute respiratory distress syndrome (ARDS).
COVID-19 resulting in ARDS has recently emerged as an important disease that predisposes patients to secondary pulmonary aspergillosis.
In recent years, liquid biopsies have emerged as a promising tool in the fields of molecular oncology and precision medicine. Liquid biopsy methodology typically analyses genomic DNA isolated from circulating tumour cells (CTCs) or circulating cell-free tumour DNA (cfDNA/ctDNA) in a peripheral blood sample, to gain insight into the genomic profile of the patients’ tumour.
Due to a rapid increase in serious infections related to especially carbapenemase producing Enterobacterales, the clinical use of the polymyxin antibiotics colistin (polymyxin E), and polymyxin B has recently resurged as salvage therapy for otherwise untreatable Gram-negative infections.